

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**“ORNITHINE ASPARTATE INJECTION”
OBTAINS DRUG REGISTRATION APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Ornithine Aspartate Injection (10ml: 5g)” (the “**Product**”) developed by CSPC Yinhu Pharmaceutical Co., Ltd* (石藥銀湖製藥有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, being the third generic drug of this type approved in China.

Ornithine aspartate is a drug for liver diseases. It is indicated for elevated blood ammonia level caused by acute or chronic liver diseases (such as all types of hepatitis, cirrhosis, fatty liver and post-hepatitis syndrome) and for the treatment of hepatic encephalopathy, especially suitable for treating mental confusion in the early and subsequent stages of hepatic coma.

The approval of the Product further enriches the Group’s product portfolio and also enhances the Group’s development in the field of liver diseases.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 4 May 2020

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

** For identification purpose only*